Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man.
The effects of quinidine on pharmacokinetics and pharmacodynamics of propranolol were investigated in a double-blind, placebo-controlled design. Healthy subjects of group A (n = 5) and group B (n = 11) were given oral propranolol (dose: group A 10 mg, group B 20 mg) with placebo or propranolol with quinidine (dose: group A 100 mg, group B 200 mg) on separate occasions. Quinidine induced a significant rise in the plasma concentrations of propranolol, and the area under the propranolol concentration-time curves (AUC) was also increased about 3-fold in both groups, indicative of an alteration of propranolol pharmacokinetics. In order to estimate the pharmacodynamic action of the pharmacokinetic interaction, the change in the heart rate during treadmill exercise testing was studied in group A. A significant inhibition of exercise-induced tachycardia was observed after administration of propranolol alone, but in combination with quinidine an even greater suppression was evident. These results indicate that the coadministration of propranolol and quinidine provides not only the potentiation of quinidine action by propranolol, which has been reported, but also the enhancement of propranolol action by quinidine, due to an increased plasma concentration of propranolol.
Yasuhara
M
M
Department of Pharmacy, Faculty of Medicine, Kyoto University, Japan.
Yatsuzuka
A
A
Yamada
K
K
Okumura
K
K
Hori
R
R
Sakurai
T
T
Kawai
C
C
D000328:Adult; D004311:Double-Blind Method; D004347:Drug Interactions; D005080:Exercise Test / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D005082:Physical Exertion / Q000502:physiology; D011433:Propranolol / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D011802:Quinidine / Q000494:pharmacology*
D011433:Propranolol; D011802:Quinidine